BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32841450)

  • 21. [Effect of AP-1 decoy oligodeoxynucleotides on neonatal rat cardiac fibroblast proliferation and collagen synthesis].
    Xie SL; Wang JF; Nie RQ; Yuan WL; Li F; Lin MH
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):811-4. PubMed ID: 18504209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice.
    Zhang X; Zhang J; Wang L; Wei H; Tian Z
    BMC Cancer; 2007 Aug; 7():149. PubMed ID: 17683579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells.
    Kim YJ; Kim JY; Lee N; Oh E; Sung D; Cho TM; Seo JH
    Biochem Biophys Res Commun; 2017 May; 486(4):1069-1076. PubMed ID: 28373070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of decoy oligodeoxynucleotides targeted to NF-kappaB in vitro and in vivo.
    Wang T; Li QH; Hao GP; Zhai J
    Asian Pac J Cancer Prev; 2010; 11(1):193-200. PubMed ID: 20593956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Oh E; Kim YJ; An H; Sung D; Cho TM; Farrand L; Jang S; Seo JH; Kim JY
    Int J Cancer; 2018 Oct; 143(8):1978-1993. PubMed ID: 29744876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of transcription factor T-cell factor 3 (TCF3) using the oligodeoxynucleotide strategy increases embryonic stem cell stemness: possible application in regenerative medicine.
    Johari B; Asadi Z; Rismani E; Maghsood F; Sheikh Rezaei Z; Farahani S; Madanchi H; Kadivar M
    Cell Biol Int; 2019 Aug; 43(8):852-862. PubMed ID: 31033094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
    Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
    Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological Inhibition of CDK8 in Triple-Negative Breast Cancer Cell Line MDA-MB-468 Increases E2F1 Protein, Induces Phosphorylation of STAT3 and Apoptosis.
    Spear JM; Lu Z; Russu WA
    Molecules; 2020 Dec; 25(23):. PubMed ID: 33291686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
    Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
    Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells.
    Ghorbani R; Gharbavi M; Sharafi A; Rismani E; Rezaeejam H; Mortazavi Y; Johari B
    Oncol Res; 2023; 32(1):101-125. PubMed ID: 38188680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of NF-kB decoy oligodeoxynucleotides in a prostate cancer cell line.
    Fang Y; Sun H; Zhai J; Zhang Y; Yi S; Hao G; Wang T
    Asian Pac J Cancer Prev; 2011; 12(10):2721-6. PubMed ID: 22320981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
    Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
    Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long noncoding RNA HOST2, working as a competitive endogenous RNA, promotes STAT3-mediated cell proliferation and migration via decoying of let-7b in triple-negative breast cancer.
    Hua K; Deng X; Hu J; Ji C; Yu Y; Li J; Wang X; Fang L
    J Exp Clin Cancer Res; 2020 Apr; 39(1):58. PubMed ID: 32248842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
    Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.
    Gariboldi MB; Ravizza R; Molteni R; Osella D; Gabano E; Monti E
    Cancer Lett; 2007 Dec; 258(2):181-8. PubMed ID: 17920763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of Transcription Factor Decoy Oligodeoxynucleotides (ODNs) for Cancer Therapy.
    Johari B; Moradi M
    Methods Mol Biol; 2022; 2521():207-230. PubMed ID: 35733000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer.
    Chen Y; Ji M; Zhang S; Xue N; Xu H; Lin S; Chen X
    J Drug Target; 2018 Dec; 26(10):920-930. PubMed ID: 29595328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
    Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
    Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.